Cabaletta Bio (CABA)
(Delayed Data from NSDQ)
$7.56 USD
+0.51 (7.23%)
Updated Jul 8, 2024 04:00 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CABA 7.56 +0.51(7.23%)
Will CABA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CABA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CABA
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
CABA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade
Other News for CABA
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
First Week of CABA February 2025 Options Trading
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Cabaletta Bio (CABA)